8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
May 12, 2026·SEC
Material company update
May 5, 2026·SEC
Enhabit, Inc.(EHAB)Earnings, Financials & Key Ratios
EHAB•NYSE
$13.80
Price updated Jun 20, 2026
AboutEnhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company also offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. As of March 31, 2022, it operated in 252 home health agencies and 99 hospice agencies across 34 states. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was incorporated in 2014 and is headquartered in Dallas, Texas. As of July 1, 2022, Enhabit, Inc. operates as a standalone company.Show more
- Revenue$1.06B+2.4%
- EBITDA$86M+203.2%
- Net Income-$5M+97.1%
- EPS (Diluted)-0.09+97.1%
- Gross Margin46.92%-3.7%
- EBITDA Margin8.14%+200.8%
- Operating Margin6.02%+154.1%
- Net Margin-0.43%+97.1%
- ROE-0.82%+96.7%
EHAB Price & Volume
Enhabit, Inc. (EHAB) stock price & volume — 10-year historical chart
Loading chart...
Persistent Reimbursement Headwinds Challenge Enhabit Operational Stability
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Strained
Financial:Adequate
Cash Flow:Mixed
Primary Risk:Medicare Advantage reimbursement compression
Key Thesis Takeaways
- Enhabit faces a challenging fundamental outlook characterized by stagnant top-line growth of only 1.9% in 2026Q1 and significant earnings volatility driven by a shift toward lower-reimbursing Medicare Advantage plans.
- While the company has demonstrated disciplined deleveraging by reducing total debt to $480.1 million, the heavy reliance on $855.3 million in goodwill poses a material risk of future impairment.
- Investors should monitor the company's ability to stabilize operating margins, which have fluctuated wildly from a negative 38.6% in 2024Q3 to a positive 11.1% in 2026Q1, before assuming a sustainable recovery.
Verdict Logic
while the company maintains a low capital intensity with CapEx/Revenue ratios consistently below 1%, the structural risk of Medicare Advantage reimbursement compression and the current P/E of -152.32 warrant a cautious wait-and-see approach.
EHAB Growth Metrics
Enhabit, Inc. (EHAB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-0.34%
3 Years-0.35%
TTM3.16%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM97.69%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM97.12%
Return on Capital
10 Years1.37%
5 Years0.27%
3 Years-2.4%
Last Year5.96%
EHAB Recent Earnings
Enhabit, Inc. (EHAB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 2/12 qtrs (17%)
Q2 2026Latest
May 20, 2026Metric
Actual
Est
EPS
$0.13+11.0%
$0.12
Rev
$265M-0.7%
$267M
Q2 2026
May 13, 2026Metric
Actual
Est
EPS
$0.13+11.0%
$0.12
Rev
$265M-0.7%
$267M
Q2 2026
May 6, 2026Metric
Actual
Est
EPS
$0.37+208.3%
$0.12
Rev
$265M-0.7%
$267M
Q2 2026
Mar 4, 2026Metric
Actual
Est
EPS
$0.14+0.0%
$0.14
Rev
$270M-0.1%
$271M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 20, 2026 | $0.13vs $0.12+11.0% | $265Mvs $267M-0.7% |
| Q2 2026 | May 13, 2026 | $0.13vs $0.12+11.0% | $265Mvs $267M-0.7% |
| Q2 2026 | May 6, 2026 | $0.37vs $0.12+208.3% | $265Mvs $267M-0.7% |
| Q2 2026 | Mar 4, 2026 | $0.14vs $0.14+0.0% | $270Mvs $271M-0.1% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Enhabit, Inc. (EHAB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.80 | $706.91M | -152.32 | 2.44% | -0.43% | -0.82% | — | |
| $105.73 | $1.97B | 20.29 | 23.21% | 6.89% | 9.34% | — | |
| $166.83 | $9.75B | 28.57 | 18.72% | 6.89% | 16.61% | — | |
| $17.00 | $2.22B | -27.87 | 6.24% | -2.28% | -2.15% | — | |
| $31.09 | $2.86B | -2.56 | 5.04% | -32.84% | -40.92% | — | |
| $16.51 | $2.05B | 13.99 | 5.12% | 2.42% | 6.57% | — |
Compare EHAB vs Peers
Enhabit, Inc. (EHAB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EHAB SEC Filings & Documents
Enhabit, Inc. (EHAB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when EHAB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EHAB Frequently Asked Questions
Enhabit, Inc. (EHAB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Enhabit, Inc.'s revenue?
Enhabit, Inc. (EHAB) reported $1.06B in revenue for fiscal year 2025. This represents a 1% decrease from $1.08B in 2020.
How fast is Enhabit, Inc. growing?
Enhabit, Inc. (EHAB) grew revenue by 2.4% over the past year. Growth has been modest.
Is EHAB profitable?
Enhabit, Inc. (EHAB) reported a net loss of $3.2M for fiscal year 2025.
Dividend & Returns
What is EHAB's return on equity?
Enhabit, Inc. (EHAB) has a return on equity (ROE) of -0.8%. Negative ROE indicates the company is unprofitable.
What is Enhabit, Inc.'s free cash flow?
Enhabit, Inc. (EHAB) generated $80.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.